Wall Street analysts predict that Genocea Biosciences (NASDAQ:GNCA) will announce ($0.14) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Genocea Biosciences’ earnings, with estimates ranging from ($0.15) to ($0.13). Genocea Biosciences posted earnings of ($0.54) per share during the same quarter last year, which would suggest a positive year over year growth rate of 74.1%. The company is expected to announce its next earnings report on Wednesday, August 8th.
According to Zacks, analysts expect that Genocea Biosciences will report full year earnings of ($0.68) per share for the current fiscal year, with EPS estimates ranging from ($0.74) to ($0.62). For the next financial year, analysts anticipate that the business will post earnings of ($0.69) per share, with EPS estimates ranging from ($0.86) to ($0.60). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that that provide coverage for Genocea Biosciences.
Genocea Biosciences (NASDAQ:GNCA) last issued its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.14) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.14).
Several analysts have commented on GNCA shares. HC Wainwright set a $5.00 price objective on shares of Genocea Biosciences and gave the stock a “buy” rating in a report on Thursday, May 10th. Zacks Investment Research upgraded shares of Genocea Biosciences from a “hold” rating to a “buy” rating in a report on Wednesday, April 18th. Cantor Fitzgerald set a $5.00 price objective on shares of Genocea Biosciences and gave the stock a “buy” rating in a report on Sunday, March 11th. ValuEngine upgraded shares of Genocea Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. Finally, Robert W. Baird started coverage on shares of Genocea Biosciences in a report on Monday, February 12th. They issued an “outperform” rating and a $3.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Genocea Biosciences presently has an average rating of “Buy” and a consensus price target of $4.41.
Hedge funds have recently added to or reduced their stakes in the company. Millennium Management LLC purchased a new position in shares of Genocea Biosciences during the fourth quarter valued at approximately $145,000. California State Teachers Retirement System lifted its holdings in shares of Genocea Biosciences by 166.6% during the first quarter. California State Teachers Retirement System now owns 125,569 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 78,469 shares during the last quarter. Schwab Charles Investment Management Inc. purchased a new position in shares of Genocea Biosciences during the first quarter valued at approximately $177,000. Birchview Capital LP lifted its holdings in shares of Genocea Biosciences by 384.6% during the first quarter. Birchview Capital LP now owns 189,000 shares of the biotechnology company’s stock valued at $198,000 after purchasing an additional 150,000 shares during the last quarter. Finally, GSA Capital Partners LLP lifted its holdings in shares of Genocea Biosciences by 266.9% during the first quarter. GSA Capital Partners LLP now owns 234,065 shares of the biotechnology company’s stock valued at $246,000 after purchasing an additional 170,265 shares during the last quarter. Hedge funds and other institutional investors own 61.94% of the company’s stock.
GNCA traded down $0.02 on Friday, hitting $0.93. The company had a trading volume of 466,899 shares, compared to its average volume of 974,686. The company has a debt-to-equity ratio of 1.00, a current ratio of 8.06 and a quick ratio of 8.06. Genocea Biosciences has a 52-week low of $0.79 and a 52-week high of $6.78. The firm has a market capitalization of $83.91 million, a PE ratio of -0.47 and a beta of 1.20.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform AnTigen Lead Acquisition System to design immunotherapies and vaccines that act through T cell immune responses. Its lead product candidate is GEN-003, an investigational immunotherapy that is in Phase III trial for the treatment of genital herpes infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.